SciELO - Scientific Electronic Library Online

 
vol.93 número5Evaluation of the Cutaneous Lymphoma International Prognostic Index in patients with early stage mycosis fungoidesAllergic contact dermatitis to shoes: contribution of a specific series to the diagnosis índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

Compartilhar


Anais Brasileiros de Dermatologia

versão impressa ISSN 0365-0596versão On-line ISSN 1806-4841

Resumo

RODRIGUEZ-ZUNIGA, Milton; TORRES, Natalie  e  GARCIA-PERDOMO, Herney. Effectiveness of acyclovir in the treatment of pityriasis rosea. A systematic review and meta-analysis. An. Bras. Dermatol. [online]. 2018, vol.93, n.5, pp.686-695. ISSN 1806-4841.  https://doi.org/10.1590/abd1806-4841.20187252.

Background:

There is a lack of evidence to support acyclovir administration in pityriasis rosea.

Objective:

To determine the efficacy of acyclovir in patients with typical pityriasis rosea.

Methods:

A systematic review and meta-analysis of experimental studies was performed in MEDLINE, SCOPUS, EMBASE and others, from January 1990 to October 2016 on acyclovir for pityriasis rosea. Random effect model was used to find the pooled Risk Ratio. Outcomes, evaluated between weeks 1 to 8, were regression of lesions, cessation of lesions, decrease of symptoms and duration of disease. Comparisons were acyclovir vs. placebo; acyclovir vs. symptomatic treatment; acyclovir vs. antibiotic; acyclovir vs. observation and combined therapy (acyclovir plus symptomatic treatment) vs. symptomatic treatment alone.

Results:

Seven papers were analyzed with 324 participants, of which 159 received acyclovir and 165 were controls. Acyclovir was superior to placebo for complete regression of lesions at week 1 (Risk Ratio 5.72, CI95% 2.36-13.88). However, combined therapy was not superior to symptomatic treatment at week 4 (Risk Ratio 1.46, CI95% 0.93-2.29). Individual studies showed the superiority of acyclovir for the control of symptoms and pruritus.

Study limitations:

We faced differences designs of trials and inconsistency between reports.

Conclusion:

Symptomatic treatment is a reasonable option for pityriasis rosea, and the addition of acyclovir is justified for the control of symptoms and pruritus.

Palavras-chave : Acyclovir; Histamine antagonists; Meta-analysis as topic; Pityriasis rosea; Pruritus.

        · texto em Inglês     · Inglês ( pdf )